Intellia Therapeutics (NTLA) Receivables - Net (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Receivables - Net of $9.1 million for Q1 2026, down 13.07% year-over-year from $10.5 million in Q1 2025, and down 3.88% quarter-over-quarter from $9.5 million in Q4 2025.
Intellia Therapeutics (NTLA) Receivables - Net (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Receivables - Net for 12 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 13.07% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (down 13.07% YoY), while the FY2025 annual figure was $9.5 million, up 11.54% from the prior year.
- Receivables - Net slipped to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
- Across five years, Receivables - Net topped out at $36.5 million in Q4 2023 and bottomed at $1.8 million in Q1 2022.
- Historically, Receivables - Net has averaged $10.8 million across 5 years, with a median of $8.9 million in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Net jumped 867.52% — and 2024, when it sank 76.64%.
- Intellia Therapeutics' Receivables - Net stood at $3.8 million in 2022, then surged by 867.52% to $36.5 million in 2023, then tumbled by 76.64% to $8.5 million in 2024, then gained by 11.54% to $9.5 million in 2025, then retreated by 3.88% to $9.1 million in 2026.
- Business Quant data shows NTLA's Receivables - Net at $9.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.32 Mn |
| Jun 30, 2026 | 7.32 Mn |
| Mar 31, 2026 | 9.13 Mn |
| Mar 31, 2026 | 9.13 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Sep 30, 2025 | 11.05 Mn |
| Sep 30, 2025 | 11.05 Mn |
| Jun 30, 2025 | 11.35 Mn |
| Jun 30, 2025 | 11.35 Mn |
| Mar 31, 2025 | 10.50 Mn |
| Mar 31, 2025 | 10.50 Mn |
| Dec 31, 2024 | 8.52 Mn |
| Dec 31, 2024 | 8.52 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Jun 30, 2024 | 12.33 Mn |
| Jun 30, 2024 | 12.33 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Mar 31, 2024 | 36.43 Mn |